Home
Forms Library
Vumerity, INN-diroximel fumarate EPAR

Vumerity, INN-diroximel fumarate EPAR 2026

Vumerity, INN-diroximel fumarate EPAR Preview on Page 1

See details

4.8 out of 5

36 votes

The document provides a comprehensive summary of the product characteristics for Vumerity, a medication containing diroximel fumarate, indicated for the treatment of relapsing-remitting multiple sclerosis in adults. It details the composition, dosage, administration guidelines, contraindications, warnings, and potential side effects associated with the drug. The document emphasizes the importance of monitoring patients for serious conditions such as progressive multifocal leukoencephalopathy (PML) and outlines necessary precautions regarding renal and hepatic function. Additionally, it includes information on pharmacokinetics, interactions with other medications, and specific considerations for special populations.

Here's how it works

01. Edit your form online

Type text, add images, blackout confidential details, add comments, highlights and more.

02. Sign it in a few clicks

Draw your signature, type it, upload its image, or use your mobile device as a signature pad.

03. Share your form with others

Send it via email, link, or fax. You can also download it, export it or print it out.

How to use or fill out Vumerity, INN-diroximel fumarate EPAR with our platform

Ease of Setup

DocHub User Ratings on G2

Ease of Use

DocHub User Ratings on G2

Click ‘Get Form’ to open the Vumerity EPAR document in the editor.
Begin by reviewing the 'Name of the Medicinal Product' section. Ensure that it states 'Vumerity 231 mg gastro-resistant hard capsules' clearly.
Proceed to the 'Qualitative and Quantitative Composition' section. Here, confirm that each capsule contains 231 mg of diroximel fumarate as listed.
In the 'Pharmaceutical Form' section, verify that it describes the product accurately as a gastro-resistant hard capsule.
Move on to 'Clinical Particulars'. This section outlines therapeutic indications and posology. Make sure to note that treatment should be initiated under physician supervision.
Fill out any relevant fields regarding contraindications and special warnings. Highlight important information such as risks associated with PML and lymphopenia.
Review the 'Undesirable Effects' section for any potential side effects that may need attention during treatment.

Start using our platform today to streamline your document editing and ensure accurate completion of your Vumerity EPAR!

See more Vumerity, INN-diroximel fumarate EPAR versions

We've got more versions of the Vumerity, INN-diroximel fumarate EPAR form. Select the right Vumerity, INN-diroximel fumarate EPAR version from the list and start editing it straight away!

Versions	Form popularity	Fillable & printable
2022	4.8 Satisfied (36 Votes)

be ready to get more

Complete this form in 5 minutes or less

Get form

Got questions?

We have answers to the most popular questions from our customers. If you can't find an answer to your question, please contact us.

Is Vumerity a good MS medication?

Most medicines for treating MS require an injection; however, newer oral medicines, like Vumerity, provide an easier treatment option. Oral options can be more convenient, but they may not be better or worse than other types of MS treatments.

How much does Vumerity cost a year?

In a statement following the approval, Biogen said weve made the decision to launch Vumerity in the US with the lowest annual WAC price for oral MS disease-modifying therapies at an annualised price of $88,000.

Is Vumerity a chemo drug?

Vumerity has anti-inflammatory and antioxidant properties. It contains the active ingredient diroximel fumarate and comes as a delayed-release oral capsule. Vumerity is not a chemotherapy or immunosuppressant drug.

What is the drug Vumerity used for?

Vumerity is a medicine used to treat adults with a type of multiple sclerosis (MS) known as relapsing-remitting MS.

Vumerity, INN-diroximel fumarate EPAR 2026

Here's how it works

How to use or fill out Vumerity, INN-diroximel fumarate EPAR with our platform